203 related articles for article (PubMed ID: 33234576)
21. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas.
Huang R; Cheung NK; Vider J; Cheung IY; Gerald WL; Tickoo SK; Holland EC; Blasberg RG
FASEB J; 2011 Dec; 25(12):4138-49. PubMed ID: 21856782
[TBL] [Abstract][Full Text] [Related]
22. TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma.
Selmi A; de Saint-Jean M; Jallas AC; Garin E; Hogarty MD; Bénard J; Puisieux A; Marabelle A; Valsesia-Wittmann S
Cancer Lett; 2015 Feb; 357(1):412-418. PubMed ID: 25475555
[TBL] [Abstract][Full Text] [Related]
23. Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer.
Guan Y; Kuo WL; Stilwell JL; Takano H; Lapuk AV; Fridlyand J; Mao JH; Yu M; Miller MA; Santos JL; Kalloger SE; Carlson JW; Ginzinger DG; Celniker SE; Mills GB; Huntsman DG; Gray JW
Clin Cancer Res; 2007 Oct; 13(19):5745-55. PubMed ID: 17908964
[TBL] [Abstract][Full Text] [Related]
24. c-myc amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of nonselected breast cancers.
Park K; Kwak K; Kim J; Lim S; Han S
Hum Pathol; 2005 Jun; 36(6):634-9. PubMed ID: 16021569
[TBL] [Abstract][Full Text] [Related]
25. Co-amplification and concomitant high levels of expression of a DEAD box gene with MYCN in human neuroblastoma.
Manohar CF; Salwen HR; Brodeur GM; Cohn SL
Genes Chromosomes Cancer; 1995 Nov; 14(3):196-203. PubMed ID: 8589036
[TBL] [Abstract][Full Text] [Related]
26. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma.
Ryan SL; Schwalbe EC; Cole M; Lu Y; Lusher ME; Megahed H; O'Toole K; Nicholson SL; Bognar L; Garami M; Hauser P; Korshunov A; Pfister SM; Williamson D; Taylor RE; Ellison DW; Bailey S; Clifford SC
Acta Neuropathol; 2012 Apr; 123(4):501-13. PubMed ID: 22139329
[TBL] [Abstract][Full Text] [Related]
27. MYC and metastasis.
Wolfer A; Ramaswamy S
Cancer Res; 2011 Mar; 71(6):2034-7. PubMed ID: 21406394
[TBL] [Abstract][Full Text] [Related]
28. Prolonged N-myc protein half-life in a neuroblastoma cell line lacking N-myc amplification.
Cohn SL; Salwen H; Quasney MW; Ikegaki N; Cowan JM; Herst CV; Kennett RH; Rosen ST; DiGiuseppe JA; Brodeur GM
Oncogene; 1990 Dec; 5(12):1821-7. PubMed ID: 2284101
[TBL] [Abstract][Full Text] [Related]
29. MYC, MYCL, and MYCN as therapeutic targets in lung cancer.
Massó-Vallés D; Beaulieu ME; Soucek L
Expert Opin Ther Targets; 2020 Feb; 24(2):101-114. PubMed ID: 32003251
[No Abstract] [Full Text] [Related]
30. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value.
Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S
Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167
[TBL] [Abstract][Full Text] [Related]
31. Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma.
Bourhis J; De Vathaire F; Wilson GD; Hartmann O; Terrier-Lacombe MJ; Boccon-Gibod L; McNally NJ; Lemerle J; Riou G; Bénard J
Cancer Res; 1991 Jan; 51(1):33-6. PubMed ID: 1988094
[TBL] [Abstract][Full Text] [Related]
32. Rare MYC-amplified Neuroblastoma With Large Cell Histology.
Matsuno R; Gifford AJ; Fang J; Warren M; Lukeis RE; Trahair T; Sugimoto T; Marachelian A; Asgharzadeh S; Maris JM; Ikegaki N; Shimada H
Pediatr Dev Pathol; 2018; 21(5):461-466. PubMed ID: 29426276
[TBL] [Abstract][Full Text] [Related]
33. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma.
Otto T; Horn S; Brockmann M; Eilers U; Schüttrumpf L; Popov N; Kenney AM; Schulte JH; Beijersbergen R; Christiansen H; Berwanger B; Eilers M
Cancer Cell; 2009 Jan; 15(1):67-78. PubMed ID: 19111882
[TBL] [Abstract][Full Text] [Related]
34. Impact of MYC in regulation of tumor cell metabolism.
Wahlström T; Henriksson MA
Biochim Biophys Acta; 2015 May; 1849(5):563-9. PubMed ID: 25038584
[TBL] [Abstract][Full Text] [Related]
35. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
[TBL] [Abstract][Full Text] [Related]
36. Wild-type sequence of MYCN in neuroblastoma cell lines.
Hogarty MD; Brodeur GM
Int J Cancer; 1999 Feb; 80(4):630-1. PubMed ID: 9935168
[No Abstract] [Full Text] [Related]
37. N-myc and noncoding RNAs in neuroblastoma.
Buechner J; Einvik C
Mol Cancer Res; 2012 Oct; 10(10):1243-53. PubMed ID: 22936790
[TBL] [Abstract][Full Text] [Related]
38. High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma.
Fredlund E; Ringnér M; Maris JM; Påhlman S
Proc Natl Acad Sci U S A; 2008 Sep; 105(37):14094-9. PubMed ID: 18780787
[TBL] [Abstract][Full Text] [Related]
39. Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance.
Shachaf CM; Gentles AJ; Elchuri S; Sahoo D; Soen Y; Sharpe O; Perez OD; Chang M; Mitchel D; Robinson WH; Dill D; Nolan GP; Plevritis SK; Felsher DW
Cancer Res; 2008 Jul; 68(13):5132-42. PubMed ID: 18593912
[TBL] [Abstract][Full Text] [Related]
40. High amplification of PVT1 and MYC predict favorable prognosis in early ovarian carcinoma.
Yamamoto A; Kurata M; Yamamoto K; Nogawa D; Inoue M; Ishibashi S; Ikeda M; Miyasaka N; Kitagawa M
Pathol Res Pract; 2020 Nov; 216(11):153175. PubMed ID: 32841774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
